MX2022007304A - Uso de lemborexant para tratamiento del insomnio. - Google Patents

Uso de lemborexant para tratamiento del insomnio.

Info

Publication number
MX2022007304A
MX2022007304A MX2022007304A MX2022007304A MX2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A MX 2022007304 A MX2022007304 A MX 2022007304A
Authority
MX
Mexico
Prior art keywords
lemborexant
pharmaceutically acceptable
acceptable salt
treating insomnia
patient
Prior art date
Application number
MX2022007304A
Other languages
English (en)
Spanish (es)
Inventor
Margaret Moline
Andrew Satlin
Ishani Landry
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2022007304A publication Critical patent/MX2022007304A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MX2022007304A 2019-12-20 2020-12-18 Uso de lemborexant para tratamiento del insomnio. MX2022007304A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962951638P 2019-12-20 2019-12-20
PCT/US2020/065891 WO2021127359A1 (en) 2019-12-20 2020-12-18 Use of lemborexant for treating insomnia

Publications (1)

Publication Number Publication Date
MX2022007304A true MX2022007304A (es) 2022-08-22

Family

ID=74191874

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007304A MX2022007304A (es) 2019-12-20 2020-12-18 Uso de lemborexant para tratamiento del insomnio.

Country Status (11)

Country Link
US (1) US20230051268A1 (https=)
EP (1) EP4076463A1 (https=)
JP (2) JP2023508011A (https=)
KR (1) KR20220119065A (https=)
CN (1) CN115003305A (https=)
AU (1) AU2020408557A1 (https=)
BR (1) BR112022012246A2 (https=)
CA (1) CA3165481A1 (https=)
MX (1) MX2022007304A (https=)
TW (1) TW202137986A (https=)
WO (1) WO2021127359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024305901A1 (en) * 2023-06-29 2026-02-12 Janssen Pharmaceutica Nv Method of treating depression using seltorexant

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0828751A4 (en) 1995-05-05 1999-01-20 Human Genome Sciences Inc HUMAN NEUROPEPTIDE RECEPTOR
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
AU2011304285B2 (en) 2010-09-22 2015-01-29 Eisai R&D Management Co., Ltd. Cyclopropane compound
BR112014019909B1 (pt) 2012-02-17 2020-01-28 Eisai R&D Man Co Ltd processo para produção de compostos úteis como antagonistas do receptor de orexina-2
ES2843952T3 (es) 2014-10-23 2021-07-21 Eisai R&D Man Co Ltd Composiciones para tratar el insomnio
CA3051830A1 (en) * 2017-01-27 2018-08-02 Neurocrine Bioscienes, Inc. Methods for the administration of certain vmat2 inhibitors

Also Published As

Publication number Publication date
CN115003305A (zh) 2022-09-02
BR112022012246A2 (pt) 2022-08-30
JP2025160480A (ja) 2025-10-22
EP4076463A1 (en) 2022-10-26
TW202137986A (zh) 2021-10-16
JP2023508011A (ja) 2023-02-28
CA3165481A1 (en) 2021-06-24
WO2021127359A1 (en) 2021-06-24
KR20220119065A (ko) 2022-08-26
AU2020408557A1 (en) 2022-08-11
US20230051268A1 (en) 2023-02-16

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
PH12019500025A1 (en) Cancer treatment combinations
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
FI3504187T3 (fi) Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten
ZA202000028B (en) Use of vibegron to treat overactive bladder
CR20230539A (es) ANÁLOGOS DE BENZOAZEPINA COMO AGENTES INHIBIDORES DE LA TORISINA CINASA DE BRUTON (Divisional 2019-0517)
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
ZA202204907B (en) Orally disintegrating pharmaceutical compositions of apixaban
AU2018282105A1 (en) Dosing of vibegron for treatment of overactive bladder
PH12019500516A1 (en) Pharmaceutical composition comprising mineralocorticoid receptor antagonist and use thereof
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
MX2022007304A (es) Uso de lemborexant para tratamiento del insomnio.
RU2020108631A (ru) Новая вспомогательная терапия для применения в способе лечения рака простаты
RU2016103099A (ru) Способ предотвращения и/или лечения хронической травматической энцефалопатии - i
HRP20230693T1 (hr) Uporaba inhibitora acetilkolinesteraze i idalopirdina za smanjenje padova kod pacijenata oboljelih od parkinsonove bolesti
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera
PH12019501607A1 (en) Tapentadol nasal composition
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
WO2016187595A3 (en) Oral pharmaceutical composition of methylergonovine
ZA202206042B (en) Treating behavioral and psychological symptoms in dementia patients
RU2018133603A (ru) Пероральная дозированная форма двух изомеров кломифена и способ ее использования для лечения вторичного гипогонадизма и минимизации побочных эффектов лекарственного препарата у мужчин
WO2016193456A3 (en) Opioid receptor antagonist for use in treating patients with severe constipation